Sunshine Biopharma (NASDAQ: SBFM) has announced the Canadian approval of Rivaroxaban—its generic equivalent of the brand Xarelto—in tablets of 2.5 mg, 10 mg, 15 mg, and 20 mg for the treatment and prevention of deep vein thrombosis and pulmonary embolism.
According to Sunshine, the global market for Rivaroxaban is estimated to reach $12.7 billion in 2026 and is set to expand to approximately $30.5 billion by 2035, growing at a CAGR of 10.19% during the forecast from 2026 to 2035.
In a statement, Dr. Steve Slilaty, CEO of Sunshine, commented, “We are pleased to introduce Rivaroxaban oral tablets as the newest addition to our expanding portfolio of high-quality generic drugs. This approval strengthens our position in the generics market and reflects our ongoing commitment to delivering affordable medicines that patients and healthcare providers can rely on.”
